Lipidated promiscuous peptides vaccine for tuberculosis-endemic regions.

Gowthaman, Uthaman and Rai, Pradeep K and Khan, Nargis and Jackson, David C and Agrewala, J N (2012) Lipidated promiscuous peptides vaccine for tuberculosis-endemic regions. Trends in molecular medicine, 18 (10). pp. 607-14. ISSN 1471-499X

[img] PDF
agrewala2012.pdf - Published Version
Restricted to Registered users only

Download (867Kb) | Request a copy
Official URL:


Despite nine decades of Bacillus Calmette--Guérin (BCG) vaccination, tuberculosis continues to be a major global health challenge. Clinical trials worldwide have proved the inadequacy of the BCG vaccine in preventing the manifestation of pulmonary tuberculosis in adults. Ironically, the efficacy of BCG is poorest in tuberculosis endemic areas. Factors such as nontuberculous or environmental mycobacteria and helminth infestation have been suggested to limit the efficacy of BCG. Hence, in high TB-burden countries, radically novel strategies of vaccination are urgently required. Here we showcase the properties of lipidated promiscuous peptide vaccines that target and activate cells of the innate and adaptive immune systems by employing a Toll-like receptor-2 agonist, S-[2,3-bis(palmitoyloxy)propyl]cysteine (Pam2Cys). Such a strategy elicits robust protection and enduring memory responses by type 1 T helper cells (Th1). Consequently, lipidated peptides may yield a better vaccine than BCG.

Item Type: Article
Additional Information: Copyright of this article belongs to Elsevier Science.
Uncontrolled Keywords: tuberculosis;vaccine; BCG;TLR-2;promiscuous peptides; T cell epitopes; dendritic cells; Pam2Cys; TB-endemic area
Subjects: Q Science > QR Microbiology > QR180 Immunology
Depositing User: Dr. K.P.S.Sengar
Date Deposited: 24 Jun 2013 11:45
Last Modified: 24 Jun 2013 12:03

Actions (login required)

View Item View Item